NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...
.png)
Copyright © 2024 globalwatchline.com. All Rights Reserved
